Literature DB >> 32538209

Possible therapeutic agents for COVID-19: a comprehensive review.

Khaled Mosaad Elhusseiny1,2,3, Fatma Abd-Elshahed Abd-Elhay4, Mohamed Gomaa Kamel4.   

Abstract

INTRODUCTION: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged in China. There are no available vaccines or antiviral drugs for COVID-19 patients. Herein, we represented possible therapeutic agents that may stand as a potential therapy against COVID-19. AREAS COVERED: We searched PubMed, Google Scholar, and clinicaltrials.gov for relevant papers. We showed some agents with potentially favorable efficacy, acceptable safety as well as good pharmacokinetic profiles. Several therapies are under assessment to evaluate their efficacy and safety for COVID-19. However, some drugs were withdrawn due to their side effects after demonstrating some clinical efficacy. Indeed, the most effective therapies could be organ function support, convalescent plasma, anticoagulants, and immune as well as antiviral therapies, especially anti-influenza drugs due to the similarities between respiratory viruses regarding viral entry, uncoating, and replication. We encourage giving more attention to favipiravir, remdesivir, and measles vaccine. EXPERT OPINION: A combination, at least dual or even triple therapy, of the aforementioned efficacious and safe therapies is greatly recommended for COVID-19. Further, patients should have a routine assessment for their coagulation and bleeding profiles as well as their inflammatory and cytokine concentrations.

Entities:  

Keywords:  Coronavirus; bat; covid-19; drug; immunization; infection; outbreak; pandemic; therapy; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32538209     DOI: 10.1080/14787210.2020.1782742

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  9 in total

Review 1.  Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.

Authors:  Kunal Nepali; Ram Sharma; Sachin Sharma; Amandeep Thakur; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2022-09-06       Impact factor: 12.771

Review 2.  Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.

Authors:  Caroline Joseph Kiriacos; Monika Rafik Khedr; Miray Tadros; Rana A Youness
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

3.  Does the rubella immunoglobulin G affect the severity of COVID- 19?  : Rubella immunoglobulin G and COVID- 19.

Authors:  Leyla Sahebi; Mohsen Hosseini; Alireza Abdollahi; Nahid Farrokhzad; Samrand Fattah Ghazi; Farzaneh Samaei Noroozi; Fereshteh Ghiasvand
Journal:  BMC Microbiol       Date:  2022-06-11       Impact factor: 4.465

4.  COVID-19 Pandemic: Need of the Hour - A Course Correction, Restructuring & Review of our Policies - An Indian Perspective.

Authors:  K Vishak Acharya; Bhaskaran Unnikrishnan; Priya Rathi; A Shreenivasa
Journal:  J Epidemiol Glob Health       Date:  2020-12-21

Review 5.  COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?

Authors:  Helen Dolk; Christine Damase-Michel; Joan K Morris; Maria Loane
Journal:  Paediatr Perinat Epidemiol       Date:  2022-03-02       Impact factor: 3.103

Review 6.  An update review of emerging small-molecule therapeutic options for COVID-19.

Authors:  Dengke Tian; Yuzhi Liu; Chengyuan Liang; Liang Xin; Xiaolin Xie; Dezhu Zhang; Minge Wan; Han Li; Xueqi Fu; Hong Liu; Wenqiang Cao
Journal:  Biomed Pharmacother       Date:  2021-02-03       Impact factor: 7.419

Review 7.  Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Sotiria G Giotaki; Konstantinos Raisakis; Charalampos Kossyvakis; Andreas Kaoukis; Fotis Kolokathis; Gerasimos Deftereos; Konstantinos E Iliodromitis; Dimitrios Avramides; Harilaos Bogossian; Gerasimos Siasos; George Giannopoulos; Bernhard Reimers; Alexandra Lansky; Jean-Claude Tardif; Spyridon Deftereos
Journal:  J Clin Med       Date:  2021-10-31       Impact factor: 4.241

8.  COVID-19 susceptibility and vaccination coverage for measles, rubella and mumps in students and healthcare workers in Trieste hospitals (NE Italy).

Authors:  Eleonora Cattaruzza; Lucia Radillo; Federico Ronchese; Corrado Negro; Francesca Rui; Paola De Michieli; Francesca Larese Filon
Journal:  Vaccine X       Date:  2022-02-25

9.  Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

Authors:  Jeffrey E Gold; William H Baumgartl; Ramazan A Okyay; Warren E Licht; Paul L Fidel; Mairi C Noverr; Larry P Tilley; David J Hurley; Balázs Rada; John W Ashford
Journal:  mBio       Date:  2020-11-20       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.